Frank Jessen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7692108/publications.pdf

Version: 2024-02-01

275 papers	27,571 citations	26610 56 h-index	6643 156 g-index
307 all docs	307 docs citations	307 times ranked	26418 citing authors

#	Article	IF	Citations
1	NIAâ€AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.4	5,861
2	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	9.4	2,697
3	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
4	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.4	1,863
5	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	9.4	1,708
6	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	4.9	1,242
7	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
8	The characterisation of subjective cognitive decline. Lancet Neurology, The, 2020, 19, 271-278.	4.9	627
9	Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Reviews Drug Discovery, 2010, 9, 560-574.	21.5	560
10	Prediction of Dementia by Subjective Memory Impairment<subtitle>Effects of Severity and Temporal Association With Cognitive Impairment</subtitle><alt-title>Dementia and Subjective Memory Impairment</alt-title>. Archives of General Psychiatry, 2010, 67, 414.	13.8	559
11	AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimer's and Dementia, 2014, 10, 76-83.	0.4	414
12	Implementation of subjective cognitive decline criteria in research studies. Alzheimer's and Dementia, 2017, 13, 296-311.	0.4	375
13	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	1.1	347
14	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	1.2	317
15	Validity of the five-item WHO Well-Being Index (WHO-5) in an elderly population. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 27-31.	1.8	243
16	Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiology of Aging, 2006, 27, 1751-1756.	1.5	243
17	Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology, 2012, 79, 1332-1339.	1.5	235
18	Subjective cognitive decline and rates of incident Alzheimer's disease and nonâ€“Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476.	0.4	232

#	Article	IF	Citations
19	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
20	A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Annals of Neurology, 1999, 45, 666-668.	2.8	205
21	Deep Brain Stimulation for Tourette-Syndrome: A Systematic Review and Meta-Analysis. Brain Stimulation, 2016, 9, 296-304.	0.7	185
22	Mild Cognitive Impairment in General Practice: Age-Specific Prevalence and Correlate Results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). Dementia and Geriatric Cognitive Disorders, 2007, 24, 307-316.	0.7	173
23	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.4	173
24	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
25	Depressionâ€”an underrecognized target for prevention of dementia in Alzheimerâ€™s disease. Translational Psychiatry, 2020, 10, 160.	2.4	138
26	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimerâ€™s disease (DELCODE). Alzheimer's Research and Therapy, 2018, 10, 15.	3.0	131
27	Patterns of subjective memory impairment in the elderly: association with memory performance. Psychological Medicine, 2007, 37, 1753-1762.	2.7	129
28	Gray matter atrophy pattern in elderly with subjective memory impairment. Alzheimer's and Dementia, 2014, 10, 99-108.	0.4	129
29	Longitudinal Predictors of Institutionalization in Old Age. PLoS ONE, 2015, 10, e0144203.	1.1	128
30	Evidence of Neuronal Compensation During Episodic Memory in Subjective Memory Impairment. Archives of General Psychiatry, 2011, 68, 845.	13.8	126
31	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. Neurobiology of Aging, 2015, 36, 601-607.	1.5	125
32	Age-related functional changes in domain-specific medial temporal lobe pathways. Neurobiology of Aging, 2018, 65, 86-97.	1.5	118
33	In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults. NeuroImage, 2017, 163, 150-159.	2.1	117
34	Prediction of Dementia in Primary Care Patients. PLoS ONE, 2011, 6, e16852.	1.1	116
35	Subjective and objective cognitive decline at the pre-dementia stage of Alzheimerâ€™s disease. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 3-7.	1.8	116
36	Cognitive performance before and after the onset of subjective cognitiveÂdecline in old age. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 194-205.	1.2	110

#	Article	IF	Citations
37	Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimerâ€™s disease. Molecular Neurodegeneration, 2020, 15, 55.	4.4	107
38	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A largeâ€scale international multicenter study. Alzheimer's and Dementia, 2015, 11, 1306-1315.	0.4	104
39	Reduced Hippocampal Activation During Encoding and Recognition of Words in Schizophrenia Patients. American Journal of Psychiatry, 2003, 160, 1305-1312.	4.0	102
40	Anticholinergic drug use and risk for dementia: target for dementia prevention. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 111-115.	1.8	99
41	Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study. Psychiatry Research - Neuroimaging, 2011, 194, 363-371.	0.9	98
42	Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. Neuropsychology Review, 2017, 27, 245-257.	2.5	97
43	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
44	In vivo Patterns of Tau Pathology, Amyloid-Î² Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 465-471.	1.2	93
45	Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 27, 404-417.	0.7	90
46	Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2016, 3, 934-939.	1.7	89
47	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	1.1	87
48	Converging Genetic and Functional Brain Imaging Evidence Links Neuronal Excitability to Working Memory, Psychiatric Disease, and Brain Activity. Neuron, 2014, 81, 1203-1213.	3.8	86
49	Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 58, 939-950.	1.2	74
50	Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimer's Research and Therapy, 2019, 11, 66.	3.0	74
51	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. Neurology, 2021, 96, .	1.5	72
52	Differential Risk of Incident Alzheimerâ€™s Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2016, 54, 1135-1146.	1.2	70
53	Cortical Thinning in Individuals with Subjective Memory Impairment. Journal of Alzheimer's Disease, 2015, 45, 139-146.	1.2	66
54	Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data. NeuroImage: Clinical, 2017, 14, 656-662.	1.4	64

#	Article	IF	Citations
55	Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults. Journal of Neuroscience, 2019, 39, 8788-8797.	1.7	64
56	Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study. Alzheimer's Research and Therapy, 2020, 12, 167.	3.0	64
57	N-Acetylaspartylglutamate (NAAG) and N-Acetylaspartate (NAA) in Patients With Schizophrenia. Schizophrenia Bulletin, 2013, 39, 197-205.	2.3	63
58	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	4.1	61
59	PLD3 in non-familial Alzheimer's disease. Nature, 2015, 520, E3-E5.	13.7	58
60	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimerâ€™s dementia. Alzheimer's Research and Therapy, 2017, 9, 84.	3.0	58
61	Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology, 2020, 95, e1134-e1143.	1.5	58
62	Prospective Associations between Single Foods, Alzheimerâ€™s Dementia and Memory Decline in the Elderly. Nutrients, 2018, 10, 852.	1.7	57
63	The CERAD Neuropsychological Assessment Battery Total Score Detects and Predicts Alzheimer Disease Dementia with High Diagnostic Accuracy. American Journal of Geriatric Psychiatry, 2014, 22, 1017-1028.	0.6	56
64	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.4	56
65	Locus coeruleus MRI contrast is reduced in Alzheimer's disease dementia and correlates with CSF Aî² levels. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 281-285.	1.2	56
66	Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0132227.	1.1	55
67	Elevated HbA1c is Associated with Increased Risk of Incident Dementia in Primary Care Patients. Journal of Alzheimer's Disease, 2015, 44, 1203-1212.	1.2	52
68	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. Alzheimer's and Dementia, 2016, 12, 872-881.	0.4	50
69	N-acetyl-aspartate (NAA) as a correlate of pharmacological treatment in psychiatric disorders: A systematic review. European Neuropsychopharmacology, 2014, 24, 1659-1675.	0.3	49
70	Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S269-76.	0.4	47
71	Longitudinal predictors of informal and formal caregiving time in community-dwelling dementia patients. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 607-616.	1.6	46
72	SUCLG2 identified as both a determinator of CSF Aî²1â€“42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6644-6658.	1.4	45

#	Article	IF	Citations
73	Anatomical Correlates of the Neuropsychiatric Symptoms in Alzheimer's Disease. Current Alzheimer Research, 2015, 12, 266-277.	0.7	45
74	Neuroanatomical Characteristics Associated With Response to Deep Brain Stimulation of the Nucleus Basalis of Meynert for Alzheimerâ€™s Disease. Neuromodulation, 2018, 21, 184-190.	0.4	43
75	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of diseaseâ€modifying therapies. Alzheimer's and Dementia, 2020, 16, 1457-1468.	0.4	43
76	Predicting primary progressive aphasias with support vector machine approaches in structural MRI data. NeuroImage: Clinical, 2017, 14, 334-343.	1.4	42
77	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. PLoS ONE, 2014, 9, e100812.	1.1	41
78	Feature Binding Deficits in Subjective Cognitive Decline and in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 48, S161-S170.	1.2	41
79	Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. Neurology, 2015, 84, 1261-1268.	1.5	41
80	Is function in instrumental activities of daily living a useful feature in predicting <scp>A</scp>lzheimer's disease dementia in subjective cognitive decline?. International Journal of Geriatric Psychiatry, 2019, 34, 193-203.	1.3	41
81	Influence of Sampling and Recruitment Methods in Studies of Subjective CognitiveÂDecline. Journal of Alzheimer's Disease, 2015, 48, S99-S107.	1.2	40
82	Caspase-8, association with Alzheimerâ€™s Disease and functional analysis of rare variants. PLoS ONE, 2017, 12, e0185777.	1.1	38
83	Functional MRI of cerebral activation during encoding and retrieval of words. , 1999, 8, 157-169.		37
84	Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 56, 1185-1196.	1.2	37
85	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.4	37
86	The Costs of Dementia From the Societal Perspective: Is Care Provided in the Community Really Cheaper than Nursing Home Care?. Journal of the American Medical Directors Association, 2014, 15, 117-126.	1.2	35
87	Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimerâ€™s disease based on multicenter diffusion tensor imaging. Journal of Neurology, 2019, 266, 2465-2474.	1.8	35
88	Neuronal correlates of delay discounting in healthy subjects and its implication for addiction: an ALE meta-analysis study. American Journal of Drug and Alcohol Abuse, 2019, 45, 51-66.	1.1	35
89	Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD). NeuroImage: Clinical, 2019, 21, 101612.	1.4	35
90	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.4	35

#	Article	IF	Citations
91	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Servicesâ€”part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	3.0	35
92	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	1.5	34
93	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S171-S191.	1.2	34
94	Reduced futureâ€oriented decision making in individuals with subjective cognitive decline: A functional MRI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 222-231.	1.2	34
95	A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests. Frontiers in Aging Neuroscience, 2018, 10, 11.	1.7	34
96	Impact of coronary heart disease on cognitive decline in Alzheimerâ€™s disease: a prospective longitudinal cohort study in primary care. British Journal of General Practice, 2017, 67, e111-e117.	0.7	33
97	Which types of mental work demands may be associated with reduced risk of dementia?. Alzheimer's and Dementia, 2017, 13, 431-440.	0.4	33
98	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31
99	Personalized risk for clinical progression in cognitively normal subjectsâ€”the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	3.0	30
100	A microRNA signature that correlates with cognition and is a target against cognitive decline. EMBO Molecular Medicine, 2021, 13, e13659.	3.3	29
101	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's diseaseâ€”Data from three memory clinic studies. Alzheimer's and Dementia, 2019, 15, 185-193.	0.4	28
102	A Comparative Study of the Different N-Acetylaspartate Measures of the Medial Temporal Lobe in Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2005, 20, 178-183.	0.7	27
103	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	1.5	27
104	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimerâ€™s disease. Neuron, 2022, 110, 1009-1022.e4.	3.8	27
105	The SCDâ€Well randomized controlled trial: Effects of a mindfulnessâ€based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 737-745.	1.8	26
106	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 782-790.	1.2	26
107	Anxiety correlates with cortical surface area in subjective cognitive decline: APOE Îµ4 carriers versus APOE Îµ4 non-carriers. Alzheimer's Research and Therapy, 2019, 11, 50.	3.0	26
108	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Servicesâ€”part 1 of 6. Alzheimer's Research and Therapy, 2021, 13, 168.	3.0	26

#	Article	IF	Citations
109	Novelty detection and repetition suppression in a passive picture viewing task: A possible approach for the evaluation of neuropsychiatric disorders. Human Brain Mapping, 2002, 17, 230-236.	1.9	25
110	A Reduction in Delay Discounting by Using Episodic Future Imagination and the Association with Episodic Memory Capacity. Frontiers in Human Neuroscience, 2017, 10, 663.	1.0	25
111	Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Alzheimer's and Dementia, 2023, 19, 487-497.	0.4	25
112	The Latent Dementia Phenotype Î´ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 49, 547-560.	1.2	23
113	Genetic Analysis of Association Between Calcium Signaling and Hippocampal Activation, Memory Performance in the Young and Old, and Risk for Sporadic Alzheimer Disease. JAMA Psychiatry, 2015, 72, 1029.	6.0	23
114	â€œAlzheimer's diseaseâ€•is neither â€œAlzheimer's clinical syndromeâ€•nor â€œdementiaâ€• Alzheimer's and Dementia, 2019, 15, 153-157.	0.4	23
115	Prevalence of abnormal Alzheimerâ€™s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Alzheimer's Research and Therapy, 2019, 11, 8.	3.0	23
116	Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea. Alzheimer's Research and Therapy, 2020, 12, 52.	3.0	22
117	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.4	22
118	Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 191.	3.0	21
119	Mortality in Individuals with Subjective Cognitive Decline: Results of the Leipzig Longitudinal Study of the Aged (LEILA75+). Journal of Alzheimer's Disease, 2015, 48, S33-S42.	1.2	20
120	Complex coevolution of depression and health-related quality of life in old age. Quality of Life Research, 2015, 24, 2713-2722.	1.5	20
121	The MOPEAD project: Advancing patient engagement for the detection of â€œhiddenâ€•undiagnosed cases of Alzheimer's disease in the community. , 2019, 15, 828-839.		20
122	Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 801-813.	1.2	19
123	Identical distribution of the ?2-macroglobulin pentanucleotide deletion in subjects with alzheimer disease and controls in a German population. American Journal of Medical Genetics Part A, 2000, 96, 775-777.	2.4	18
124	Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S1-S3.	1.2	18
125	Bupropion for the Treatment of Apathy in Alzheimer Disease. JAMA Network Open, 2020, 3, e206027.	2.8	18
126	Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. Psychotherapy and Psychosomatics, 2021, 90, 341-350.	4.0	18

#	Article	IF	Citations
127	TREM2 rare variant p.R47H is not associated with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 23, 109-111.	1.1	17
128	Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 610-618.	1.2	17
129	Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkersâ€"results from the DELCODE study. Alzheimer's Research and Therapy, 2020, 12, 131.	3.0	17
130	Multimodal MRI analysis of basal forebrain structure and function across the Alzheimerâ€™s disease spectrum. NeuroImage: Clinical, 2020, 28, 102495.	1.4	17
131	Amyloid pathology but notAPOEÎµ4 status is permissive for tau-related hippocampal dysfunction. Brain, 2022, 145, 1473-1485.	3.7	17
132	Computational dissection of human episodic memory reveals mental process-specific genetic profiles. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4939-48.	3.3	16
133	Level of education mitigates the impact of tau pathology on neuronal function. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1787-1795.	3.3	16
134	Alzheimerâ€™s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. Dementia and Geriatric Cognitive Disorders, 2022, 51, 182-192.	0.7	16
135	Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimerâ€™s Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. Journal of Alzheimer's Disease, 2019, 72, 455-465.	1.2	15
136	Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimerâ€™s disease spectrum. NeuroImage: Clinical, 2021, 29, 102533.	1.4	15
137	Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 626974.	1.7	15
138	Gene-gene interaction between interleukin-6 and ?2-macroglobulin influences the risk for Alzheimer's disease. Annals of Neurology, 2000, 47, 138-139.	2.8	14
139	Prediction of dementia of Alzheimer type by different types of subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, 1745-1749.	0.4	14
140	Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status. Journal of Alzheimer's Disease, 2021, 79, 493-509.	1.2	14
141	Donâ€™t forget about tau: the effects of ApoE4 genotype on Alzheimerâ€™s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairmentâ€"data from the Dementia Competence Network. Journal of Neural Transmission, 2022, 129, 477-486.	1.4	14
142	Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimerâ€™s disease: a voxel-based lesion mapping study. Alzheimer's Research and Therapy, 2015, 7, 27.	3.0	13
143	Exploring Genetic Associations of Alzheimerâ€™s Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. Frontiers in Aging Neuroscience, 2018, 10, 340.	1.7	12
144	Neurocognitive disorders in ICDâ€11: the debate and its outcome. World Psychiatry, 2018, 17, 229-230.	4.8	12

#	Article	IF	Citations
145	Resting-State Network Alterations Differ between Alzheimerâ€™s Disease Atrophy Subtypes. Cerebral Cortex, 2021, 31, 4901-4915.	1.6	12
146	Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimerâ€™s Disease Spectrum. Journal of Alzheimer's Disease, 2022, 85, 1267-1282.	1.2	12
147	Wishes and preferences for an online lifestyle program for brain healthâ€"A mixed methods study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 141-149.	1.8	11
148	Cognitive behavioural therapy for the treatment of late life depression: study protocol of a multicentre, randomized, observer-blinded, controlled trial (CBTlate). BMC Psychiatry, 2019, 19, 423.	1.1	11
149	Biomarker-Based Risk Prediction of Alzheimerâ€™s Disease Dementia in Mild Cognitive Impairment: Psychosocial, Ethical, and Legal Aspects. Journal of Alzheimer's Disease, 2021, 80, 601-617.	1.2	11
150	Association of N-Acetylaspartate and Cerebrospinal Fluid AÎ²42 in Dementia. Journal of Alzheimer's Disease, 2011, 27, 393-399.	1.2	10
151	Quality of health care with regard to detection and treatment of mental disorders in patients with coronary heart disease (MenDis-CHD): study protocol. BMC Psychology, 2019, 7, 21.	0.9	10
152	P3â€591: A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1352.	0.4	8
153	Computerâ€assisted prediction of clinical progression in the earliest stages of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 726-736.	1.2	8
154	Informal caregiversâ€™ perspectives on health of and (potentially inappropriate) medication for (relatively) independent oldest-old people â€“ a qualitative interview study. BMC Geriatrics, 2018, 18, 169.	1.1	8
155	Promoting stigma coping and empowerment in patients with schizophrenia and depression: results of a cluster-RCT. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 501-511.	1.8	8
156	Identification of undiagnosed dementia cases using a webâ€based preâ€screening tool: The MOPEAD project. Alzheimer's and Dementia, 2021, 17, 1307-1316.	0.4	8
157	Subjective cognitive decline in idiopathic ParkinsonÂ´s disease: A systematic review. Ageing Research Reviews, 2022, 74, 101508.	5.0	8
158	Cognitive, Genetic, Brain Volume, and Diffusion Tensor Imaging Markers as Early Indicators of Dementia. Journal of Alzheimer's Disease, 2020, 77, 1443-1453.	1.2	7
159	Impaired self-awareness of cognitive deficits in Parkinson's disease relates to cingulate cortex dysfunction. Psychological Medicine, 2023, 53, 1244-1253.	2.7	7
160	Advance directives for future dementia can be modified by a brief video presentation on dementia care: An experimental study. PLoS ONE, 2018, 13, e0197229.	1.1	6
161	Not all, but specific types of cognitive complaints predict decline to MCI. Neurology, 2018, 91, 153-154.	1.5	6
162	What are we trying to prevent in Alzheimer disease?. Dialogues in Clinical Neuroscience, 2019, 21, 27-34.	1.8	6

#	Article	IF	Citations
163	Cross-Cultural Longitudinal Study on Cognitive Decline (CLoCODE) for Subjective Cognitive Decline in China and Germany: A Protocol for Study Design. Journal of Alzheimer's Disease, 2022, , 1-15.	1.2	6
164	No association of the variant rs11887120 in DNMT3A with cognitive decline in individuals with mild cognitive impairment. Epigenomics, 2016, 8, 593-598.	1.0	5
165	Detection and treatment of mental disorders in patients with coronary heart disease (MenDis-CHD): A cross-sectional study. PLoS ONE, 2020, 15, e0243800.	1.1	5
166	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 87, 545-555.	1.2	5
167	A Cost-Consequence Analysis of Different Screening Procedures in Alzheimerâ€™s Disease: Results from the MOPEAD Project. Journal of Alzheimer's Disease, 2021, 83, 1149-1159.	1.2	4
168	Harmonisation and Between-Country Differences of the Lifetime of Experiences Questionnaire in Older Adults. Frontiers in Aging Neuroscience, 2021, 13, 740005.	1.7	4
169	A Comparison of Operational Definitions for Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2022, 88, 1663-1678.	1.2	4
170	ICâ€Pâ€046: Abnormal Functional Connectivity Within Default Mode Network in Persons With Subjective Cognitive Decline: Selfâ€Reflection of Own Memory Deficits?. Alzheimer's and Dementia, 2016, 12, P39.	0.4	3
171	P2â€339: Abnormal Functional Connectivity within Default Mode Network in Persons with Subjective Cognitive Decline: Selfâ€Reflection of Own Memory Deficits?. Alzheimer's and Dementia, 2016, 12, P772.	0.4	3
172	One step towards dementia prevention. Lancet Neurology, The, 2018, 17, 294-295.	4.9	3
173	Refining the understanding of typical Alzheimer disease. Nature Reviews Neurology, 2019, 15, 623-624.	4.9	3
174	Association of a CAMK2A genetic variant with logical memory performance and hippocampal volume in the elderly. Brain Research Bulletin, 2020, 161, 13-20.	1.4	3
175	Complementary preâ€screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project. Alzheimer's and Dementia, 2021, , .	0.4	3
176	ICâ€Pâ€161: 18Fâ€PI2620 TAUâ€PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTIâ€CENTER EVALUATION. Alzheimer's and Dementia, 2019, 15, P128.	0.4	3
177	Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk. JAMA - Journal of the American Medical Association, 2015, 314, 1177.	3.8	2
178	[ICâ€Pâ€080]: USEFULNESS AND STABILITY OF MULTICENTER DIFFUSION TENSOR IMAGING AS AN EARLY MARKER FOR SUBJECTIVE COGNITIVE DECLINE AND AMNESTIC MILD COGNITIVE IMPAIRMENT: FIRST RESULTS FROM THE PROSPECTIVE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P66.	0.4	2
179	[P3â€“437]: LATENTâ€FACTOR STRUCTURE OF THE DELCODE STUDY NEUROPSYCHOLOGICAL TEST BATTERY. Alzheimer's and Dementia, 2017, 13, P1136.	0.4	2
180	[P3â€“528]: PROSPECTIVE ASSOCIATIONS BETWEEN VITAMINS, METABOLITES, AND OVERALL DEMENTIA IN THE OLDESTâ€OLD. Alzheimer's and Dementia, 2017, 13, P1180.	0.4	2

#	Article	IF	Citations
181	[P1â€“122]: WHAT IS MEMORABLE IS CONSERVED ACROSS HEALTHY AGING, EARLY ALZHEIMER's DISEASE, AND NEURAL NETWORKS. Alzheimer's and Dementia, 2017, 13, P287.	0.4	2
182	Structural and Functional Magnetic Resonance Imaging. PET Clinics, 2013, 8, 407-430.	1.5	1
183	O4-04-04: TOWARD FINE MAPPING AND FUNCTIONAL CHARACTERIZATION OF GENOME-WIDE ASSOCIATION STUDY-IDENTIFIED LOCUS RS74615166 (TRIP4) FOR ALZHEIMER'S DISEASE. , 2014, 10, P257-P258.		1
184	P4â€153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Nonâ€AD in Memory Clinic and Communityâ€Based Cohorts. Alzheimer's and Dementia, 2016, 12, P1073.	0.4	1
185	[P2â€“390]: LOCAL AND GLOBAL RESTING STATE ALTERATIONS IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER's DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT. Alzheimer's and Dementia, 2017, 13, P779.	0.4	1
186	[P3â€“218]: TAU PLASMA LEVELS IN SUBJECTIVE COGNITIVE DECLINE: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P1021.	0.4	1
187	P4â€068: LEVELS OF THE ASTROCYTEâ€DERIVED PROTEINS GFAP AND S100B IN THE CEREBROSPINAL FLUID OF HEALTHY INDIVIDUALS AND ALZHEIMER'S DISEASE PATIENTS AT DIFFERENT DISEASE STAGES. Alzheimer's and Dementia, 2018, 14, P1458.	0.4	1
188	Feasibility of mobile appâ€based assessment of memory functions: Insights from a citizen science study. Alzheimer's and Dementia, 2020, 16, e039149.	0.4	1
189	Decreased cortical thickness in individuals with subjective cognitive decline with and without CSFâ€ADâ€pathology: Data from the DELCODE Study. Alzheimer's and Dementia, 2020, 16, e044741.	0.4	1
190	Preâ€screening models for patient engagement: The MOPEAD project. Alzheimer's and Dementia, 2020, 16, e044796.	0.4	1
191	Attention in subjective cognitive decline â€“ Authors' reply. Lancet Neurology, The, 2020, 19, 566-567.	4.9	1
192	Editorial: Exploring Reliable Markers and Prediction Indexes for the Progression From Subjective Cognitive Decline to Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 760920.	1.7	1
193	Social Cognition in Patients with Amnestic Mild Cognitive Impairment and Mild Dementia of the Alzheimer Type. Journal of Alzheimer's Disease, 2021, 83, 1173-1186.	1.2	1
194	What are we trying to prevent in Alzheimer disease?. Dialogues in Clinical Neuroscience, 2019, 21, 27-34.	1.8	1
195	Memorability analysis for diagnostic photographs in cognitive assessment: Linking behavioral performance with biomarker status. Alzheimer's and Dementia, 2021, 17, .	0.4	1
196	Lifelong music practice as reserve factor: Associations with cognition and brain structure in older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	1
197	The effect of a mindfulnessâ€based versus health selfâ€management intervention on cognitive performance in older adults with subjective cognitive decline (SCD): The SCDâ€Well randomized controlled trial. Alzheimer's and Dementia, 2021, 17, .	0.4	1
198	P1-022: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH CSF AMYLOID B 1-42, DEPRESSIVE SYMPTOMS AND EPISODIC MEMORY PERFORMANCE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT. , 2014, 10, P312-P312.		0

#	Article	IF	Citations
199	P3â€237: 1Hâ€MRS in Subjects with SCD, MCI and Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P917.	0.4	0
200	P2â€087: Genetic Determinants of Alzheimer's Disease Progression: Exploratory Analysis of International Genomics of Alzheimer Project (IGAP) Genetic Markers in MMSE Rate of Decline and GDS. Alzheimer's and Dementia, 2016, 12, P642.	0.4	0
201	P2-348: Impact of Non-Pharmacologic Interventions on Cognitive, Behavioral, and Emotional Functioning in Older Adults with Subjective Cognitive Decline: A Systematic Review of Controlled Trials. , 2016, 12, P777-P777.		0
202	P2â€351: â€˜Healthy Dietâ€™ and Cognitive Status in the Oldest Old. Alzheimer's and Dementia, 2016, 12, P779.	0.4	0
203	IC-P-143: 1H-MRS in Subjects With SCD, MCI and AD. , 2016, 12, P106-P106.		0
204	P1-010: Face Name Associative Recognition is Associated with Alzheimerâ€™s Disease Biomarkers in Patients with Subjective Cognitive Decline. , 2016, 12, P402-P403.		0
205	P1â€120: Exploring International Genomics of Alzheimerâ€™s Project (IGAP) Genetic Markers' Effect on Age at Onset of Dementia in Alzheimerâ€™s Disease Patients. Alzheimer's and Dementia, 2016, 12, P448.	0.4	0
206	P2â€335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. Alzheimer's and Dementia, 2016, 12, P770.	0.4	0
207	[P2â€“200]: IN VIVO TAUOPATHY MEASURED WITH [18F]â€AVâ€1451 IS DIFFERENTIALLY RELATED TO CSF BIOMARKERS OF TAU IN ALZHEIMER's DISEASE: THE INFLUENCE OF AMYLOID DEPOSITION. Alzheimer's and Dementia, 2017, 13, P683.	0.4	0
208	[P3â€“395]: USING NEUROMELANINâ€SENSITIVE MRI TO CHARACTERISE THE STRUCTURAL INTEGRITY OF THE HUMAN LOCUS COERULEUS AT DIFFERENT STAGES OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1114.	0.4	0
209	[P1â€“320]: INTERPRETATIVE PHENOMENOLOGICAL ANALYSIS OF COGNITIVE COMPLAINTS REVEALS COMMONALITIES AND DIFFERENCES BETWEEN MEMORYâ€CLINIC PATIENTS, DEPRESSIVE PATIENTS, AND HEALTHY ELDERLY. Alzheimer's and Dementia, 2017, 13, P377.	0.4	0
210	[P2â€“074]: MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT. Alzheimer's and Dementia, 2017, 13, P634.	0.4	0
211	[P3â€“164]: FUNCTIONAL CHARACTERIZATION OF A RARE GENETIC VARIANT IN PHOSPHOLIPASE Cî²2 WHICH IS ASSOCIATED WITH A BENEFICIAL EFFECT ON THE PROGRESSION OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P997.	0.4	0
212	[P3â€“372]: DOMAINâ€SPECIFIC MNEMONIC DISCRIMINATION IN AGEING AND EARLY STAGES OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1100.	0.4	0
213	[P3â€“393]: ROBUST AUTOMATED DETECTION OF SUBJECTIVE COGNITIVE DECLINE AND PRODROMAL ALZHEIMER's DISEASE BASED ON MULTICENTER RESTINGâ€STATE FUNCTIONAL CONNECTIVITY: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P1112.	0.4	0
214	[P3â€“566]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1195.	0.4	0
215	[P4â€“139]: APPLICATION OF THE â€˜A/T/Nâ€™ BIOMARKER CLASSIFICATION SYSTEM IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: CONVERSION RATES TO AD AND OTHER DEMENTIAS. Alzheimer's and Dementia, 2017, 13, P1310.	0.4	0
216	[P4â€“166]: EVIDENCE FOR AMYLOID PATHOLOGY IN SCDâ€DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P1325.	0.4	0

#	Article	IF	Citations
217	[P4â€“223]: THE PHENOMENOLOGY AND THE NEURONAL CORRELATES OF EPISODIC FUTURE IMAGINATION IN PERSONS WITH SUBJECTIVE COGNITIVE DECLINE AND HEALTHY CONTROLS. Alzheimer's and Dementia, 2017, 13, P1354.	0.4	0
218	[P4â€“248]: QUALITY ASSURANCE IN DELCODE: A MULTIâ€CENTER NEUROIMAGING STUDY. Alzheimer's and Dementia, 2017, 13, P1372.	0.4	0
219	[ICâ€Pâ€030]: CONNECTIVITY OF THE LEFT FRONTAL CORTEX ATTENUATES DETRIMENTAL EFFECTS OF CSFâ€TAU ON MEMORY IN PRECLINICAL AND CLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P28.	0.4	0
220	[ICâ€Pâ€139]: THE PHENOMENOLOGY AND THE NEURONAL CORRELATES OF EPISODIC FUTURE IMAGINATION IN PERSONS WITH SUBJECTIVE COGNITIVE DECLINE AND HEALTHY CONTROLS. Alzheimer's and Dementia, 2017, 13, P105.	0.4	0
221	[TDâ€Pâ€020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P166.	0.4	0
222	[P1â€“554]: OPTIMAL HARMONIZATION OF COGNITIVE MEASURES ENHANCES THE DETECTION OF GENETIC EFFECTS ON ALZHEIMER's DISEASE PROGRESSION: A COMPARISON OF SIX STATISTICAL APPROACHES IN 1796 MCI PATIENTS FROM THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P506.	0.4	0
223	P3â€616: EICOSAPENTAENOIC ACID BUT NOT DOCOSAHEXAENOIC ACID IS ASSOCIATED WITH ALZHEIMER'S DISEASE RISK IN THE OLDESTâ€OLD. Alzheimer's and Dementia, 2018, 14, P1366.	0.4	0
224	P1â€379: CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P443.	0.4	0
225	P2â€534: STATUS QUO OF HEALTH LITERACY IN INDIVIDUALS AT RISK FOR DEVELOPING ALZHEIMER'S DISEASE: FIRST DATA OF A SYSTEMATIC REVIEW. Alzheimer's and Dementia, 2018, 14, P941.	0.4	0
226	P1â€311: RISK KNOWLEDGE OF MCI PATIENTS IN PREDICTIVE DIAGNOSIS OF ALZHEIMER'S DEMENTIA: PRELIMINARY DATA OF A MIXED METHOD APPROACHâ€”THE PREDADQOL STUDY. Alzheimer's and Dementia, 2018, 14, P410.	0.4	0
227	P3â€545: â€œMOVE ON UPâ€: THE MOBI ASSISTâ€PROGRAMME. Alzheimer's and Dementia, 2018, 14, P1331.	0.4	0
228	P3â€327: NEUROPSYCHIATRIC SYMPTOMS IN ATâ€RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AD BIOMARKERS: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1206.	0.4	0
229	P2â€434: EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P879.	0.4	0
230	P1â€512: ASSESSMENT OF SOCIAL COGNITIVE ABILITIES IN PATIENTS WITH MCI AND MILD AD COMPARED TO YOUNGER AND OLDER HEALTHY CONTROLS. Alzheimer's and Dementia, 2018, 14, P526.	0.4	0
231	P2â€455: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P894.	0.4	0
232	P3â€289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EUROâ€SCD STUDY. Alzheimer's and Dementia, 2018, 14, P1191.	0.4	0
233	FTS4â€01â€02: SUBJECTIVE AND VERY FIRST OBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P1398.	0.4	0
234	P1â€028: OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES. Alzheimer's and Dementia, 2018, 14, P276.	0.4	0

#	Article	IF	Citations
235	P3â€366: MULTICENTER RESTING STATE FUNCTIONAL CONNECTIVITY IN PRODROMAL AND DEMENTIA STAGES OF ALZHEIMER'S DISEASE: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1228.	0.4	0
236	ICâ€Pâ€155: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P131.	0.4	0
237	P3â€122: APOEâ€Îµ4 MODULATES LEVELS OF OMEGAâ€3 AND OMEGAâ€6 FATTY ACIDS IN ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1114.	0.4	0
238	F4â€08â€04: SUBJECTIVE COGNITIVE DECLINE, AS MEASURED WITH A STRUCTURED INTERVIEW, IS RELATED TO AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1396.	0.4	0
239	P4â€074: COUNSELING AND DISCLOSURE IN RISK PREDICTION OF ALZHEIMER'S DEMENTIA: IMPACT ON MCI PATIENTS AND THEIR CAREGIVERSâ€"THE PREDADQOL STUDY. Alzheimer's and Dementia, 2018, 14, P1462.	0.4	0
240	F1â€04â€03: EFFECTS OF AGE AND TAU MEASURED IN CSF ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P207.	0.4	0
241	P1â€458: LEVEL OF BRAIN RESERVE ASSOCIATED WITH SPATIAL EXTENT OF TAUâ€NEURODEGENERATION PATTERN IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P494.	0.4	0
242	P2â€431: RELATIONSHIP BETWEEN LOCAL RESTING STATE ACTIVITY, Î²â€AMYLOID DEPOSITION AND MEMORY PERFORMANCE IN THE DZNE: LONGITUDINAL COGNITIVE IMPAIRMENT AND DEMENTIA STUDY (DELCODE). Alzheimer's and Dementia, 2018, 14, P877.	0.4	0
243	P1â€159: RARE VARIANTS IN PLCG2, ABI3, AND TREM2 GENES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE IN AN ARGENTINIAN SAMPLE: IS IT A EUROPEAN HERITAGE?. Alzheimer's and Dementia, 2018, 14, P337.	0.4	0
244	P3â€304: MODELS OF PATIENT ENGAGEMENT IN ALZHEIMER'S DISEASE (MOPEAD): A EUROPEAN MULTINATIONAL PROJECT TO DEVELOP AND TEST INNOVATIVE PATIENT ENGAGEMENT STRATEGIES. Alzheimer's and Dementia, 2018, 14, P1197.	0.4	0
245	COMMENTARY: COMBINATION THERAPY FOR ALZHEIMERâ€™S DISEASE â€“ THE NEXT STEP. Journal of prevention of Alzheimer's disease, The, 2019, 6, 1-1.	1.5	0
246	ICâ€Pâ€122: ALTERATIONS OF INTRINSIC CONNECTIVITY IN POSTERIOR DEFAULT MODE NETWORK ACROSS AT RISK STAGES OF ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2019, 15, P101.	0.4	0
247	ICâ€Pâ€028: PATTERNS OF INCREASED AND DECREASED PRECUNEUS FUNCTIONAL CONNECTIVITY IN SCD DEPENDING ON AMYLOID STATUS. Alzheimer's and Dementia, 2019, 15, P35.	0.4	0
248	ICâ€Pâ€016: CORTICAL AMYLOID BURDEN CORRELATES WITH ATROPHY OF THE POSTERIOR PART OF THE NUCLEUS BASALIS MEYNERT IN AMYLOIDâ€POSITIVE SCD. Alzheimer's and Dementia, 2019, 15, P25.	0.4	0
249	Identification of a Cascade of Changes in Activities of Daily Living Preceding Short-Term Clinical Deterioration in Mild Alzheimerâ€™s Disease Dementia via Lead-Lag Analysis. Journal of Alzheimer's Disease, 2020, 76, 1005-1015.	1.2	0
250	Evaluation of evidence grades in psychiatry and psychotherapy guidelines. BMC Psychiatry, 2020, 20, 503.	1.1	0
251	Comparison of Patient and Proxy Assessment of Patient-Centeredness in the Care of Coronary Heart Disease: A Cross Sectional Survey Using the PACIC-S11.1. Journal of Primary Care and Community Health, 2020, 11, 215013272097623.	1.0	0
252	Anosognosia in Alzheimerâ€™s disease associated with tau accumulation and hypometabolism in frontal areas. Alzheimer's and Dementia, 2020, 16, e039416.	0.4	0

#	Article	IF	Citations
253	General practitionersâ€™ opinion on early and preâ€dementia diagnosis of AD: A MOPEAD project survey in five European countries. Alzheimer's and Dementia, 2020, 16, e040357.	0.4	0
254	Altered resting state activity associated with anosognosia in Alzheimer's clinical syndrome: Findings from the DELCODE study. Alzheimer's and Dementia, 2020, 16, e040416.	0.4	0
255	Gender differences in the perception of subjective vs. objective cognitive decline: Baseline data from the SCDâ€Well Trial. Alzheimer's and Dementia, 2020, 16, e040428.	0.4	0
256	Awareness of cognitive decline and CSFâ€biomarkers in memory clinic patients: Results from the DELCODEâ€study. Alzheimer's and Dementia, 2020, 16, e044744.	0.4	0
257	The effects of Mediterranean diet on memory and Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2020, 16, e045349.	0.4	0
258	Psychotherapeutic interventions in individuals at risk for Alzheimerâ€™s dementia: A systematic review. Alzheimer's and Dementia, 2020, 16, e047269.	0.4	0
259	What are we trying to prevent in Alzheimer disease?. Dialogues in Clinical Neuroscience, 2019, 21, 27-34.	1.8	0
260	Difference in Amyloid Load Between Single Memory Domain and Multidomain Subjective Cognitive Decline: A Study from the SILCODE. Journal of Alzheimer's Disease, 2022, 85, 1573-1582.	1.2	0
261	Association between SCDâ€Plus features and GDS factors in subjective cognitive decline and healthy controls in the studies DELCODE and SILCODE. Alzheimer's and Dementia, 2021, 17, .	0.4	0
262	Characterization of the NIAâ€AA Research Framework stage 2 in the longitudinal multicenter DELCODE study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
263	Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0
264	In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
265	Feasibility of short imaging protocols for [¹⁸ F]Plâ€2620 tauâ€PET in progressive supranuclear palsy. Alzheimer's and Dementia, 2021, 17, .	0.4	0
266	Artificial neural network visualization methods reveal diagnostically relevant brain regions to detect Alzheimerâ€™s disease: The first step towards comprehensive artificial intelligence. Alzheimer's and Dementia, 2021, 17, .	0.4	0
267	INSPIRATION: Study design and preliminary results of a crosssectional risk ADâ€profiling study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
268	Prediction of amyloidâ€positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize numberâ€neededâ€toâ€screen. Alzheimer's and Dementia, 2021, 17, .	0.4	0
269	Title is missing!. , 2020, 15, e0243800.		0
270	Title is missing!. , 2020, 15, e0243800.		0

#	Article	IF	Citations
271	Title is missing!. , 2020, 15, e0243800.		0
272	Title is missing!. , 2020, 15, e0243800.		0
273	Title is missing!. , 2020, 15, e0243800.		0
274	Title is missing!. , 2020, 15, e0243800.		0
275	Automated segmentation of the locus coeruleus in aging and Alzheimer's disease using 3T neuromelanin-sensitive MRI.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052564.	0.4	0